Dr. John N Bonfiglio- Chairman of the Board
Dr. John N. Bonfiglio is a seasoned well-respected CEO with over 30 years experience in the pharmaceutical/biotechnology business. Dr. Bonfiglio started his career with Allergan pharmaceuticals as a scientist and moved into project management, strategic marketing and business development. Two of his projects while at Allergan are now marketed products- Tazarotene and AlphaGan. He spent 3 years at Baxter HealthCare before starting a career in small biotech companies. He rose to the position of CEO at Peregrine Pharmaceuticals where he turned around the struggling and financially strapped company by reducing the burn rate, licensing technologies and raising capital in the public markets.
Dr. Bonfiglio was named COO at Cypress Bioscience while the company was struggling to reinvent itself as neuropharmaceutical company. He was responsible for in-licensing Milnacipran from Pierre Fabre which was subsequently commercialized in the US for fibromyalgia by Cypress and Forest Labs (nder the trade name Savella). He then joined the Immune Response Corporation as CEO and was responsible for raising over $50M and restarting clinicals in the HIV and MS areas. Recently he was the CEO at Argos Therapeutics a privately held autologous cellular therapy company and raised $35M through a series C financing. His tenure at Argos produced Phase 2 clinical data in renal cell carcinoma, which led to an IPO and subsequent financings.
Recently he completed a successful stint at Oragenics in Tampa, Fl. Here he completed two strategic deals with Intrexon Corporation, raised $29M in three financings under very favorable terms, relisted the company on the NYSE:MKT and refocused the company on new novel and proprietary antibiotics – all while reducing the burn rate. He was also responsible for completing a strategic marketing and sales initiative with the company’s OTC probiotic product line by hiring an in-house sales team and selling directly to the dentists’ offices.
Dr. Bonfiglio most recently served as Board member and President and COO a for Tapimmune, a public company in the T-cell vaccine space. In this capacity he has helped raise over $10M, uplist TapImmune to NASDAQ, formulate a clinical strategy and get new awareness to investors interested in the company.
Dr. Bonfiglio brings a strong strategic mindset and a philosophy of meeting milestones and keeping costs down. His expertise extends to most therapeutic areas with emphasis on oncology, infectious disease, auto-immune disease and cell therapies as well as diagnostics and probiotics.